MMP2和MMP9在乳腺癌中的表达及与淋巴结转移的关系研究

Expression of MMP2, MMP9 in human breast cancer and the relationship with node metastasis

目的探讨基质金属蛋白酶2（MMP2）和基质金属蛋白酶9（MMP9）在乳腺癌中的表达及其与侵袭、淋巴结转移及预后的关系。方法用免疫组化检测130例乳腺癌组织和10例乳腺良性病变组织中MMP2和MMP9表达。结果在130例乳腺癌组织中，MMP2和MMP9阳性表达率分别为83．08％（108／130）和71．54％（93／130），明显高于乳腺良性病变（P〈0．01），且随肿块大小，临床分期的增加呈明显升高趋势，差异有统计学意义（P〈0．05，P〈0．01）。腋下淋巴结转移组中MMP2和MMP9的高表达明显高于无淋巴结转移组（P〈0．01）。结论乳腺癌中MMP2和MMP9的表达与淋巴结转移密切相关，可作为判断乳腺癌淋巴结转移和预后的指标。

Objective To investigate the expression of matrix metalloproteinase 2 （MMP2） and MMP9 in the breast cancer and its relationship with tumor invasive potentiality, node metastasis and prognostic significance. Methods 130 cases of breast cancer and 10 cases of breast benign disease were studied by immunohistochemical staining with MMP2, MMP9 monoclonal antibodies. Results The positive expression rate of MMP2 and MMP9 were 83.08% （108/130） and 71.54% （93/130） in the breast cancers, which was significantly higher than those in breast benign disease （ P 〈0.01 ）. The expressions of MMP2 and MMP9 obviously increased with tumor sizes and clinical staging（ P 〈 0. 05, P 〈 0. 01 ）. Over expression of MMP2 and MMP9 in the breast cancers with axillary lymph node metastases were significantly higher than those without lymph node metastases （ P 〈 0. 01 ）. Conclusions The expression of MMP2 and MMP9 was closely correlated to lymph node metastasis, and may act as markers for lymph node metastasis and prognostic in breast cancer.